BFRI.US Biofrontera Inc

Healthcare Biotechnology USA Stocks
0.7001 USD
Close of Nov 14, 2026
0.5547 1.66
Market cap
USD 10.4M
P/E
-
P/B
2.31x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is BFRI.US undervalued?

Graham number

The Graham number of Biofrontera Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Biofrontera Inc fundamental analysis

No fundamental analysis for Biofrontera Inc yet.

Biofrontera Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Biofrontera Inc

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Full company profile